- GSK plc seeks to broaden the age range for its RSV vaccine usage in Europe.
- Analysts predict an average target price for GSK with moderate downside potential.
- GuruFocus suggests potential growth based on its GF Value estimation.
GSK plc (GSK, Financial) has made a strategic move by submitting an application to the European Medicines Agency aiming to expand the demographic for its respiratory syncytial virus (RSV) vaccine to adults aged 18 and above. The decision on this application is expected by the first half of 2026. Concurrently, GSK is actively working towards obtaining similar approvals in the United States and Japan.
Wall Street Analysts Forecast
According to estimates from seven analysts, the one-year price target for GSK PLC (GSK, Financial) averages at $39.28, ranging from a high of $45.00 to a low of $35.43. This average target suggests a potential downside of 5.05% from the current stock price of $41.37. For further insights and data, visit the GSK PLC (GSK) Forecast page.
Brokerage consensus from nine firms places GSK PLC's (GSK, Financial) recommendation at an average of 2.9, which translates to a "Hold" status. The rating scale used by analysts spans from 1 (Strong Buy) to 5 (Sell).
GuruFocus Valuation Perspective
From the perspective of GuruFocus metrics, the projected GF Value for GSK PLC (GSK, Financial) one year from now is $46.39. This projection implies an upside potential of 12.15% when compared to the current market price of $41.365. The GF Value is a proprietary calculation by GuruFocus, reflecting the fair trading value of the stock, anchored on historical trading multiples, past business growth, and anticipated future performance. Detailed analysis and data can be accessed on the GSK PLC (GSK) Summary page.
